🏅 FDA Orphan Designation

Clolar

clofarabine

Manufacturer: Genzyme Corporation

Indicated for:

Acute lymphoblastic leukemiaOrphanPrecursor T-cell acute lymphoblastic leukemia

FDA-Approved Indications (2)

Acute lymphoblastic leukemiaOrphan Designation

Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens

Precursor T-cell acute lymphoblastic leukemia

Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Population: pediatric 1 to 21 years

Indications & Usage

1 INDICATIONS AND USAGE Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. (1)

💙 Support Programs

View all →

Clolar

Genzyme Corporation

Clolar

Genzyme Corporation

CLOFARABINE

Sanofi

Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.